Table 2

 Summary of the main data and therapeutic response to infliximab at 38 weeks of treatment

DataBaseline (mean)38 Weeks (mean)Reduction in values (%)*p Value
*Intention to treat analysis.
TJC, tender joint count; SJC, swollen joint count; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; VAS pain, visual analogue scale for pain (0–10 cm); VAS physician, physician’s assessment of global disease on a visual analogue scale (0–10 cm); VAS patient, patient’s assessment of global disease on a visual analogue scale (0–10 cm); HAQ, Health Assessment Questionnaire; PASI, Psoriasis Area and Severity Index.
TJC20.76.073.1<0.001
SJC13.51.777.7<0.001
CRP (mg/l)23.55.859.4<0.001
ESR (mm/1st h)38.517.237.2<0.001
VAS pain (cm)6.22.750.2<0.001
VAS physician (cm)5.82.261.6<0.001
VAS patient (cm)5.82.758.4<0.001
HAQ1.50.854.3<0.001
PASI5.70.147.8<0.001